ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 334 filers reported holding ROYALTY PHARMA PLC in Q4 2022. The put-call ratio across all filers is 0.58 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $5,428,871 | +20.8% | 205,873 | +39.1% | 0.01% | +14.3% |
Q1 2024 | $4,494,851 | +145.9% | 148,003 | +127.4% | 0.01% | +133.3% |
Q4 2023 | $1,828,154 | -43.3% | 65,082 | -45.3% | 0.00% | -40.0% |
Q3 2023 | $3,226,512 | +23.1% | 118,884 | +39.4% | 0.01% | 0.0% |
Q2 2023 | $2,620,769 | -37.4% | 85,256 | -26.6% | 0.01% | -28.6% |
Q1 2023 | $4,187,731 | -20.5% | 116,229 | -12.8% | 0.01% | -30.0% |
Q4 2022 | $5,268,846 | +6.0% | 133,321 | +7.8% | 0.01% | 0.0% |
Q3 2022 | $4,969,000 | +105.9% | 123,673 | +115.5% | 0.01% | +400.0% |
Q2 2022 | $2,413,000 | +164.9% | 57,382 | +145.2% | 0.00% | +100.0% |
Q1 2022 | $911,000 | -18.1% | 23,405 | -16.2% | 0.00% | 0.0% |
Q4 2021 | $1,113,000 | +82.5% | 27,917 | +65.3% | 0.00% | – |
Q3 2021 | $610,000 | +45.6% | 16,885 | +65.2% | 0.00% | – |
Q2 2021 | $419,000 | +94.0% | 10,223 | +106.0% | 0.00% | – |
Q1 2021 | $216,000 | -12.9% | 4,963 | 0.0% | 0.00% | – |
Q4 2020 | $248,000 | – | 4,963 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SIGULER GUFF ADVISERS, LLC | 6,761,970 | $263,446,000 | 59.92% |
Memorial Sloan Kettering Cancer Center | 1,128,255 | $43,957,000 | 50.90% |
Vantage Consulting Group Inc | 2,727,854 | $106,277,000 | 41.47% |
Indie Asset Partners, LLC | 756,874 | $29,488,000 | 22.15% |
Overbrook Management Corp | 723,250 | $28,178,000 | 6.25% |
Brown University | 621,759 | $24,224,000 | 5.93% |
Geo Capital Gestora de Recursos Ltd | 200,692 | $8,527,000 | 3.82% |
Lagoda Investment Management, L.P. | 141,560 | $5,515,000 | 2.97% |
Greytown Advisors Inc. | 131,143 | $5,109,000 | 2.47% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 2,025,610 | $78,918,000 | 2.41% |